For the year ending 2025-12-31, ONMD had $413K increase in cash & cash equivalents over the period. -$7,516K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Stock warrant expense | 0 |
| Non-cash sepa commitment fee | 0 |
| Gain on forgiveness of ceba loan | 0 |
| Net loss | -2,801 |
| Depreciation and amortization | 65 |
| Stock-based compensation expense | 2,032 |
| Change in fair value of warrant liabilities | 56 |
| Change in fair value of convertible notes | 1,285 |
| Change in fair value of sepa derivative liabilities | 216 |
| Realized gain on sale of crypto assets bitcoin | 922 |
| Gain on troubled debt restructurings | 5,569 |
| Loss on debt extinguishment | -41 |
| Non-cash interest | 45 |
| Accounts receivable | 282 |
| Prepaid expenses and other current assets | -194 |
| Accounts payable and accrued expenses | 366 |
| Deferred revenues | -172 |
| Change in fair value of crypto assets bitcoin | -945 |
| Net cash used in operating activities | -7,503 |
| Purchases of property and equipment | 13 |
| Purchases of crypto assets bitcoin | 2,750 |
| Proceeds from sales of crypto assets bitcoin | 5,070 |
| Net cash provided by (used in) investing activities | 2,307 |
| Proceeds from issuance of shareholder loans | 0 |
| Proceeds from issuance of yorkville note, net of issuance costs | 0 |
| Proceeds from line of credit borrowings | 0 |
| Repayment of ceba loan | 0 |
| Repayment of shareholder loan | 0 |
| Repayment of line of credit borrowings | 0 |
| Proceeds from private placements, net of issuance costs | 2,497 |
| Proceeds from related party subscription agreements, net of issuance costs | 1,697 |
| Proceeds from yorkville sepa | 2,537 |
| Proceeds from exercises of helena termination warrants | 60 |
| Repayment of deferred underwriter fees | 500 |
| Repayment of yorkville note | 262 |
| Repayment of loans payable | 401 |
| Payment of issuance costs in connection with non-cash conversions of liabilities | 19 |
| Net cash provided by financing activities | 5,609 |
| Net increase in cash and cash equivalents | 413 |
| Net increase in cash and cash equivalents | 413 |
| Cash and cash equivalents at beginning year | 172 |
| Cash and cash equivalents at end of year | 585 |
OneMedNet Corp (ONMD)
OneMedNet Corp (ONMD)